BPI is Informa’s largest European biopharm event. With the upward trend showing an increasing need for the production of biopharmaceuticals at a consistently higher quality and volumes, the importance of developing an effective and efficient bioprocess have never been more significant.
The BioProcess International Europe Summit is closely regarded as Europe’s key conference for addressing issues, breakthroughs and developments covering the whole development cycle for the bioprocessing industry. Topics covered include biosimilars, biobetters, manufacturing strategies, QbD, cell culture and upstream processing, recovery and purification, formulation and analytical strategies.
• No of Attendee’s: 400+
• No of Participating Companies: 176
• Conference Rating: 4.2 out of 5
• Networking Rating: 4.5 out of 5
Categories
downstream processing
cell culture
upstream processing
novel therapies
analytical methods
formulation and pre formulation
adc
biosimilars
continuous bioprocessing
continuous manufacturing
bpi
Contacts
Daniel Barry
Press contactDrBPI Europe Project Manager
With BioProcessing International Europe less than a month away, we sat down with Nigel Darby, VP of BioProcess GE Healthcare Life Sciences, to discuss the current challenges facing the bioprocessing industry and how the biomanufacturing has changed over the past few years. More mature industry “I think if you look at the biomanufacturing industry today, you see a transition to a much more c
Although continuous processing / continuous manufacturing is not a new concept, application in the biopharmaceutical industry is currently not widely accepted. However with advances in technology and emergence of new product types and markets companies are becoming more willing to embrace this.
BPI Europe - In your opinion, what are the top three challenges facing biotech/ bioprocessing at the moment? AL - Amongst the top challenges seen today in biotech, manufacturing cost control is likely to be one of the most important, as it is directly related to producers’ profit margin and the prices of medicinal drugs.. The challenge is even more obvious with the increasing share of
September 10, 2013 – Tokyo, Japan – JSR Corporation (President: Mitsunobu Koshiba) announced today that it has expanded its Life Sciences initiative with a strategic investment in Natrix Separations, the developer of Natrix™ HD Membrane Technology and Advective™ Chromatography. The companies have also entered into a global distribution agreement for commercialization of Natrix bioprocess produ
Next-generation therapies such as bi-specifics, fusion proteins and fragments offer tremendous benefits on paper, but it’s the bioprocessing departments that have to develop the new production methods, switch to new platforms and investigate new capture steps.
Biosimilars are big business. The global biologics market reached $125 billion in 2011, and is predicted to top $150 billion by the end of 2016. Of this, roughly $60 billion will be in off-patent sales.
Peter Greenleaf is stepping down down as president of Gaithersburg-based biotechnology giant MedImmune, according to a company spokesman, to take the helm of parent company AstraZeneca’s Latin America business. He will be replaced by Bahija Jallal, who currently serves as MedImmune’s executive vice president of research and development. Jallal joined the company in 2006 as vice president of tra
The pursuit of Biosimilars, Antibody-Drug Conjugates and New Processing Technologies will set the trend for biomanufacturing in 2013; so says research from the industry's leading conference and exhibition, BioProcess International Europe.
The FDA’s Breakthrough Therapy Designation is big news. As of December 29, 2014, the US Agency has given 16 approvals to drugs designated as Breakthrough Therapies, 11 of them first time approvals for novel drugs. For production and analytical teams the question is: “How does this impact us?”